Viacyte have developed a line of
pancreatic endoderm cells (PEC - 01).
Novocell scientists pioneered a differentiation process that successfully engineers hES cells into definitive and
pancreatic endoderm cells necessary for pancreas formation.
Pancreatic endoderm derived from human embryonic stem cells generates glucose - responsive insulin - secreting cells in vivo.
Not exact matches
The scientists then progressed these
endoderm cells two more steps, first into
pancreatic precursor cells, and then into fully - functional
pancreatic beta cells.
ViaCyte's patent portfolio covers many of the intermediary cell types generated when human pluripotent stem cells progress along the differentiation pathway to
pancreatic progenitor cells, including mesendoderm and definitive
endoderm.
In November 2014, BioPharma-Reporter.com reported that ViaCyte won a U.S. patent to manufacture human
pancreatic progenitor cells from
endoderm (embryonic stem) cells.
Moreover, ES cell differentiation in vitro recapitulates events that take place during early embryonic development including the formation of the three germ layers of ectoderm, mesoderm and
endoderm, and the emergence of endothelial, hematopoietic, cardiac, neuronal and hepatic or
pancreatic cells [8], [9].
San Diego, CA (March 31, 2009)-- Novocell, Inc., a stem cell engineering company, today announced that it has received U.S. Patent 7,510,876 with claims covering human definitive
endoderm cells, an essential cell for generating not only
pancreatic type cells, which Novocell is developing for use as a cell therapy for diabetes, but also other
endoderm lineage - derived tissues and organs such as lungs, intestine, liver, thymus and thyroid.